Abstract
Background
Elevated concentrations of cystatin C are associated with greater cardiovascular morbidity and mortality. We sought to determine whether elevated concentrations of cystatin C were associated with inducible ischemia in patients with coronary heart disease (CHD).
Methods
We measured serum cystatin C and performed exercise treadmill testing with stress echocardiography in a cross‐sectional study of 899 outpatients with CHD.
Results
Among the 241 participants in the highest quartile of cystatin C (>1.30 mg/L), 38% had inducible ischemia, compared with 13% of those in the lowest quartile of cystatin C < 0.92 mg/L; adjusted odds ratio [OR]: 2.1; 95% confidence interval [CI]: 1.2 to 3.8; p = 0.01). However, this association differed in participants with and without a history of coronary artery bypass graft (CABG), as well as in users and nonusers of beta‐blockers and statins (p values for interaction < 0.1). Among participants without a history of CABG, 35% of those in the highest quartile and 9% of those in the lowest quartile of cystatin C had inducible ischemia (adjusted OR: 3.05; 95% CI: 1.3–6.9; p = 0.008). Among participants who were not using beta‐blockers, 44% of those in the highest quartile and 7% in the lowest quartile of cystatin C had inducible ischemia (adjusted OR: 5.3; 95% CI: 1.8–15.5; p = 0.002). Among participants who were not using statins, 39% of participants in the highest quartile and 4% of those in the lowest quartile had inducible ischemia (adjusted OR: 10.3; 95% CI: 2.5–43.3; p = 0.001).
Conclusions
Elevated levels of cystatin C are independently associated with inducible ischemia among outpatients with stable coronary disease. Copyright © 2009 Wiley Periodicals, Inc.
Keywords: cystatin C, inducible ischemia, coronary heart disease
Full Text
The Full Text of this article is available as a PDF (124.0 KB).
References
- 1. James SK, Lindahl B, Siegbahn A, Stridsberg M, Venge P, et al.: N‐terminal pro‐brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: A Global Utilization of Strategies To Open occluded arteries (GUSTO)‐IV substudy. Circulation 2003;108:275–281. [DOI] [PubMed] [Google Scholar]
- 2. Al Suwaidi J, Reddan DN, Williams K, Pieper KS, Harrington RA, et al.: Prognostic implications of abnormalities in renal function in patients with acute coronary syndromes. Circulation 2002;106:974–980. [DOI] [PubMed] [Google Scholar]
- 3. Januzzi JL Jr, Snapinn SM, DiBattiste PM, Jang IK, Theroux P: Benefits and safety of tirofiban among acute coronary syndrome patients with mild to moderate renal insufficiency: Results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM‐PLUS) trial. Circulation 2002;105:2361–2366. [DOI] [PubMed] [Google Scholar]
- 4. Santopinto JJ, Fox KA, Goldberg RJ, Budaj A, Pinero G, et al.: Creatinine clearance and adverse hospital outcomes in patients with acute coronary syndromes: Findings from the global registry of acute coronary events (GRACE). Heart 2003;89:1003–1008. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5. Januzzi JL, Cannon CP, DiBattiste PM, Murphy S, Weintraub W, et al.: Effects of renal insufficiency on early invasive management in patients with acute coronary syndromes (The TACTICS‐TIMI 18 Trial). Am J Cardiol 2002;90:1246–1249. [DOI] [PubMed] [Google Scholar]
- 6. Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, et al.: Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004;351:1285–1295. [DOI] [PubMed] [Google Scholar]
- 7. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296–1305. [DOI] [PubMed] [Google Scholar]
- 8. Sarnak MJ, Katz R, Stehman‐Breen CO, Fried LF, Jenny NS, et al.: Cystatin C concentration as a risk factor for heart failure in older adults. Ann Intern Med 2005;142:497–505. [DOI] [PubMed] [Google Scholar]
- 9. Shlipak MG, Katz R, Fried LF, Jenny NS, Stehman‐Breen CO, et al.: Cystatin‐C and mortality in elderly persons with heart failure. J Am Coll Cardiol 2005;45:268–271. [DOI] [PubMed] [Google Scholar]
- 10. Shlipak MG, Sarnak MJ, Katz R, Fried LF, Seliger SL, et al.: Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med 2005;352:2049–2060. [DOI] [PubMed] [Google Scholar]
- 11. Jernberg T, Lindahl B, James S, Larsson A, Hansson LO, et al.: Cystatin C: A novel predictor of outcome in suspected or confirmed non‐ST‐elevation acute coronary syndrome. Circulation 2004;110:2342–2348. [DOI] [PubMed] [Google Scholar]
- 12. Armstrong WF, Zoghbi WA: Stress echocardiography: Current methodology and clinical applications. J Am Coll Cardiol 2005;45:1739–1747. [DOI] [PubMed] [Google Scholar]
- 13. Senior R, Monaghan M, Becher H, Mayet J, Nihoyannopoulos P: Stress echocardiography for the diagnosis and risk stratification of patients with suspected or known coronary artery disease: A critical appraisal. Supported by the British Society of Echocardiography. Heart 2005;91:427–436. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14. Cortigiani L, Picano E, Coletta C, Chiarella F, Mathias W, et al.: Safety, feasibility, and prognostic implications of pharmacologic stress echocardiography in 1482 patients evaluated in an ambulatory setting. Am Heart J 2001;141:621–629. [DOI] [PubMed] [Google Scholar]
- 15. Ruo B, Rumsfeld JS, Hlatky MA, Liu H, Browner WS, et al.: Depressive symptoms and health‐related quality of life: The Heart and Soul Study. JAMA 2003;290:215–221. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16. Coll E, Botey A, Alvarez L, Poch E, Quinto L, et al.: Serum cystatin C as a new marker for noninvasive estimation of glomerular filtration rate and as a marker for early renal impairment. Am J Kidney Dis 2000;36:29–34. [DOI] [PubMed] [Google Scholar]
- 17. Newman DJ, Thakkar H, Edwards RG, Wilkie M, White T, et al.: Serum cystatin C measured by automated immunoassay: A more sensitive marker of changes in GFR than serum creatinine. Kidney Int 1995;47:312–318. [DOI] [PubMed] [Google Scholar]
- 18. Gokkusu CA, Ozden TA, Gul H, Yildiz A: Relationship between plasma cystatin C and creatinine in chronic renal diseases and Tx‐transplant patients. Clin Biochem 2004;37:94–97. [DOI] [PubMed] [Google Scholar]
- 19. Curhan G: Cystatin C: A marker of renal function or something more? Clin Chem 2005;51:293–294. [DOI] [PubMed] [Google Scholar]
- 20. Koenig W, Twardella D, Brenner H, Rothenbacher D: Plasma concentrations of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events: More than simply a marker of glomerular filtration rate. Clin Chem 2005;51:321–327. [DOI] [PubMed] [Google Scholar]
- 21. Liu J, Sukhova GK, Sun JS, Xu WH, Libby P, et al.: Lysosomal cysteine proteases in atherosclerosis. Arterioscler Thromb Vasc Biol 2004;24:1359–1366. [DOI] [PubMed] [Google Scholar]
- 22. Ablad B, Bjorkman JA, Gustafsson D, Hansson G, Ostlund‐Lindqvist AM, et al.: The role of sympathetic activity in atherogenesis: effects of beta‐blockade. Am Heart J 1988;116:322–327. [DOI] [PubMed] [Google Scholar]
- 23. Brehm BR, Bertsch D, von Fallois J, Wolf SC: Beta‐blockers of the third generation inhibit endothelin‐1 liberation, mRNA production and proliferation of human coronary smooth muscle and endothelial cells. J Cardiovasc Pharmacol 2000;36:S401–S403. [DOI] [PubMed] [Google Scholar]
- 24. Rosenson RS, Brown AS: Statin use in acute coronary syndromes: Cellular mechanisms and clinical evidence. Curr Opin Lipidol 2002;13:625–630. [DOI] [PubMed] [Google Scholar]
- 25. Boyle JJ: Macrophage activation in atherosclerosis: Pathogenesis and pharmacology of plaque rupture. Curr Vasc Pharmacol 2005;3:63–68. [DOI] [PubMed] [Google Scholar]